These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36628904)

  • 21. Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.
    Wilczynski O; Boisbouvier A; Radoszycki L; Cotté FE; Gaudin AF; Lemasson H
    J Med Internet Res; 2022 Jan; 24(1):e25792. PubMed ID: 35014969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.
    Saito Z; Fujita K; Okamura M; Ito T; Yamamoto Y; Kanai O; Hashimoto M; Nakatani K; Sawai S; Mio T
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1405. PubMed ID: 33934572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.
    de Arruda FN; Oonk MHM; Mourits MJE; de Graeff P; Jalving M; de Bock GH
    Gynecol Oncol; 2019 Jun; 153(3):610-615. PubMed ID: 30935716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.
    Ran J; Wang J; Bi N; Jiang W; Zhou Z; Hui Z; Liang J; Feng Q; Wang L
    Radiat Oncol; 2017 Dec; 12(1):195. PubMed ID: 29197373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
    Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
    J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
    Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
    J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
    Boekhout AH; Rogiers A; Jozwiak K; Boers-Sonderen MJ; van den Eertwegh AJ; Hospers GA; de Groot JWB; Aarts MJB; Kapiteijn E; Ten Tije AJ; Piersma D; Vreugdenhil G; van der Veldt AA; Suijkerbuijk KPM; Rozeman EA; Neyns B; Janssen KJ; van de Poll-Franse LV; Blank CU
    Acta Oncol; 2021 Jan; 60(1):69-77. PubMed ID: 32924708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer.
    van der Kloot WA; Uchida Y; Inoue K; Kobayashi K; Yamaoka K; Nortier HW; Kaptein AA
    Chin Clin Oncol; 2016 Feb; 5(1):3. PubMed ID: 26932427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients.
    Takamori S; Shimokawa M; Komiya T
    Thorac Cancer; 2021 Nov; 12(21):2943-2948. PubMed ID: 34612011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reference data of the EORTC QLQ-C30 questionnaire: five consecutive annual assessments of approximately 2000 representative Dutch men and women.
    Mols F; Husson O; Oudejans M; Vlooswijk C; Horevoorts N; van de Poll-Franse LV
    Acta Oncol; 2018 Oct; 57(10):1381-1391. PubMed ID: 29912607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    van Walree IC; Hamaker ME; van de Poll-Franse LV; Vos MC; Boll D; van Huis-Tanja LH; Ezendam NPM
    Gynecol Oncol; 2019 May; 153(2):391-398. PubMed ID: 30772033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients.
    Alwhaibi A; Alenazi MA; Alnofaie SD; Aldekhail AM; Alanazi RJ; Alghadeer S; Alghamdi AA; Alanazi SA
    J Clin Med; 2024 Aug; 13(16):. PubMed ID: 39201062
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
    Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
    BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data.
    Larsson M; Ljung L; Johansson BB
    Eur J Cancer Care (Engl); 2012 Sep; 21(5):642-9. PubMed ID: 22519874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.